Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9600 posts found.

ipsen-logo-big

Ipsen acquires Blueprint drug and moves further into ultra-rare disease

October 17, 2019 Research and Development

Ipsen has announced that through its subsidiary Clementia Pharmaceuticals, it has entered into an exclusive, worldwide license agreement for the …
News

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019 Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
News

AstraZeneca receives FDA Priority Review for breast cancer drug

October 17, 2019 Research and Development

AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription …
News
andrew_dickinson

Gilead appoints Andrew Dickinson as CFO

October 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November. Dickinson currently …
Appointment
_dsc6281_1

Medical cannabis: Riding the wave

October 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma

Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …
Feature
shutterstock_273326141

Alexion to acquire Achillion Pharma for $930 million

October 16, 2019 Research and Development, Sales and Marketing Alexion, achillion, merger, pharma

Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
News
eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019 Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
News

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019 Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …
News
mitigating-burdens-of-tbi

Tranexamic acid to prevent brain bleeds could save thousands of lives

October 15, 2019 Research and Development

A large controlled clinical trial has linked the early use of tranexamic acid to a small fall in the risk …
News
takeda_world

Takeda sheds 30 products in emerging markets in $200m deal

October 15, 2019 Research and Development

Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa …
News
_dsc6538

Medical cannabis: On to greener pastures?

October 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Feature

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019 Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
News
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019 Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
News

Three focus areas to accelerate breakthrough drugs to market

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva

The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
Feature
Thought Leadership
jim_greenwood

Biotechnology Innovation Organization Chief to step down after US 2020 elections

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma

The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
News
The Gateway to Local Adoption Series

Latest content

Five Facts about the menopause

March 6, 2026

Zello Appoints Kevin Bailey as Group Chief Medical Officer

March 6, 2026

BioDuro establishes joint manufacturing venture with Cenra

March 6, 2026

Symbiosis appoints Joanne Anderson as Chief Commercial Officer

March 6, 2026

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026